Cellectis Cut to Underweight From Overweight by Barclays
Barclays downgraded Cellectis to underweight from overweight and cut its price target to $1.30 from $9.00,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.